The Chronic Lymphocytic Leukemia Channel is supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver).
The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2025 | Real-world ibrutinib plus venetoclax in frontline CLL/SLL: REALITY-WW and REALITY-2 outcomes
Paolo Ghia, MD, Vita-Salute San Raffaele University, Milan, Italy, discusses early real-world outcomes with fixed-duration ibrutinib plus venetoclax in previously untreated chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) from the REALITY worldwide (WW) and REALITY-2 cohort studies. He highlights high early response rates and a safety profile consistent with clinical trials, including in older patients. This interview took place at the 67th ASH Annual Meeting and Exposition, held in Orlando, FL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
